PRESS KITS
These press kits are intended for journalists and analysts/investors
RELATED TOPICS
We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV/AIDS.
This link will take you to a non-ViiV Healthcare website. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third-parties.
About us
We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS.
About HIV
Our medicines
Our research
We are dedicated to treat, prevent and hopefully one day, cure HIV. Find out about our research initiatives in the fight against HIV.
Community engagement
We work actively with communities affected by HIV and AIDS around the world. Read about our community engagement initiatives.
Ending HIV
We are the only pharmaceutical company solely focused on curing HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.
News & Events
Our Media centre contains a range of resources including our latest and archived press releases and news updates, conferences and events we attend, our image and video library and social media information.
About us
We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS.
About HIV
Our medicines
Our research
We are dedicated to treat, prevent and hopefully one day, cure HIV. Find out about our research initiatives in the fight against HIV.
Community engagement
We work actively with communities affected by HIV and AIDS around the world. Read about our community engagement initiatives.
Ending HIV
We are the only pharmaceutical company solely focused on curing HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.
News & Events
Our Media centre contains a range of resources including our latest and archived press releases and news updates, conferences and events we attend, our image and video library and social media information.
December 21, 2021
ViiV Healthcare announces FDA approval of Apretude (cabotegravir long-acting), the first and only long-acting injectable option for HIV prevention
September 28, 2021
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
November 17, 2020
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
November 9, 2020
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
CABENUVA (cabotegravir, rilpivirine) Prescribing Information
ViiV Healthcare
410 Blackwell Street
Durham
North Carolina USA
27701
Tel: +1 877 ViiVUSA (+1 877 844 8872)
Report an adverse event
To report a suspected side effect, please use our online reporting form.
©2021 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.
You are about to leave a ViiV Healthcare website. By clicking this link, you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.
This is an archived press release which may not reflect current medical knowledge and should not be used as a source of information on the present label, safety data or efficacy data for ViiV Healthcare products and/or their uses. Please refer to your nationally approved label or summary of product characteristics for up-to-date product information.